These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 19564813)

  • 1. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B; Di Maio M
    J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hepatocellular carcinoma - long-term treatable disease].
    Fínek J
    Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
    Ahn HK; Lee S; Sun JM; Lee J; Park SH; Park JO; Park YS; Kang WK; Lim HY
    Invest New Drugs; 2012 Aug; 30(4):1768-72. PubMed ID: 21720741
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
    Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
    Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
    [No Abstract]   [Full Text] [Related]  

  • 6. Sorafenib in hepatocellular carcinoma.
    Josephs DH; Ross PJ
    Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib in advanced hepatocellular carcinoma.
    Spinzi G; Paggi S
    N Engl J Med; 2008 Dec; 359(23):2497-8; author reply 2498-9. PubMed ID: 19052134
    [No Abstract]   [Full Text] [Related]  

  • 8. Sorafenib-induced destructive thyroiditis.
    Iavarone M; Perrino M; Viganò M; Beck-Peccoz P; Fugazzola L
    Thyroid; 2010 Sep; 20(9):1043-4. PubMed ID: 20825302
    [No Abstract]   [Full Text] [Related]  

  • 9. Sorafenib for liver cancer: the horizon broadens.
    Johnson P; Billingham L
    Lancet Oncol; 2009 Jan; 10(1):4-5. PubMed ID: 19111238
    [No Abstract]   [Full Text] [Related]  

  • 10. Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Llanos L; Bellot P; Zapater P; Pérez-Mateo M; Such J
    Am J Gastroenterol; 2009 Jan; 104(1):257-8. PubMed ID: 19098892
    [No Abstract]   [Full Text] [Related]  

  • 11. Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
    Coriat R; Gouya H; Mir O; Ropert S; Vignaux O; Chaussade S; Sogni P; Pol S; Blanchet B; Legmann P; Goldwasser F
    PLoS One; 2011 Feb; 6(2):e16978. PubMed ID: 21340026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
    Saab S; McTigue M; Finn RS; Busuttil RW
    Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].
    Amano R; Yamada N; Noda E; Kubo N; Tanaka H; Muguruma K; Takashima T; Yashiro M; Maeda K; Onoda N; Sawada T; Nakata B; Ohira M; Ishikawa T; Hirakawa K
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2676-8. PubMed ID: 21224677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
    Boige V; Barbare JC; Rosmorduc O;
    Gastroenterol Clin Biol; 2008 Jan; 32(1 Pt. 1):3-7. PubMed ID: 18341970
    [No Abstract]   [Full Text] [Related]  

  • 15. Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting.
    Verset G; Maréchal R; Bali MA; Devière J; Van Laethem JL
    Ann Oncol; 2010 Jun; 21(6):1381-1382. PubMed ID: 20332137
    [No Abstract]   [Full Text] [Related]  

  • 16. [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].
    Ishizaki M; Kaibori M; Matsui K; Nakatake R; Matsushima H; Sakaguchi T; Kwon AH
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2493-5. PubMed ID: 22202424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sorafenib in advanced hepatocellular carcinoma.
    Palmer DH
    N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065750
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hepatocellular carcinoma].
    Yamashita T; Arai K; Kaneko S
    Nihon Rinsho; 2010 Oct; 68(10):1861-5. PubMed ID: 20954330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
    Xu L; Li P; Lin XJ; Yuan YF; Zhang YQ; Chen MS
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):58-61. PubMed ID: 19538872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
    Zhu AX; Clark JW
    Oncologist; 2009 Jan; 14(1):67-9. PubMed ID: 19147690
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.